Natalia Bernardi Videira

Natalia Bernardi Videira

Auto-generated profile, based on publicly available information

Natalia Bernardi Videira

Affygility Solutions

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
HFHelder Veras Ribeiro Filho
Helder Veras Ribeiro Filho
ITIzabella Luisa Tambones
Izabella Luisa Tambones
MDMarieli Mariano Gonçalves Dias
Marieli Mariano Gonçalves Dias
NVNatalia Bernardi Videira
Natalia Bernardi Videira
MBMarjorie Bruder
Marjorie Bruder
AFAna Carolina Migliorini Figueira
Ana Carolina Migliorini Figueira

12 April 2018 in PPAR Research
Verified
Journal Article
Open access
PDF file
NVNatália Bernardi Videira
Natália Bernardi Videira
FBFernanda Aparecida Heleno Batista
Fernanda Aparecida Heleno Batista
ACArtur Cordeiro
Artur Cordeiro
AFAna Carolina Migliorini Figueira
Ana Carolina Migliorini Figueira
Peroxisome proliferator-activated receptor beta/delta (PPARß/δ) is considered a therapeutic target for metabolic disorders, cancer, and cardiovascular diseases. Here, we developed one pipeline for the screening of PPARß/δ agonists, which reduces the cost, time, and false-positive hits. The first step is an optimized 3-day long cellular transactivation assay based on reporter-gene technology, which is supported by automated liquid-handlers. This primary screening is followed by a confirmatory transactivation assay and by two biophysical validation methods (thermal shift assay (TSA) and (ANS) fluorescence quenching), which allow the calculation of the affinity constant, giving more information about the selected hits. All of the assays were validated using well-known commercial agonists providing trustworthy data. Furthermore, to validate and test this pipeline, we screened a natural extract library (560 extracts), and we found one plant extract that might be interesting for PPARß/δ modulation. In conclusion, our results suggested that we developed a cheaper and more robust pipeline that goes beyond the single activation screening, as it also evaluates PPARß/δ tertiary structure stabilization and the ligand affinity constant, selecting only molecules that directly bind to the receptor. Moreover, this approach might improve the effectiveness of the screening for agonists that target PPARß/δ for drug development.

30 August 2023 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
NVNatália Bernardi Videira
Natália Bernardi Videira
VNVijayalekshmi Nair
Vijayalekshmi Nair
VPValérie Paquet
Valérie Paquet
DCDean Calhoun
Dean Calhoun

14 April 2025 in Evidence-Based Toxicology
Verified
Journal Article
Open access
MPMilica D. Pavlovic
Milica D. Pavlovic
MLMalgorzata Lagisz
Malgorzata Lagisz
NVNatália B. Videira
Natália B. Videira
JMJulia M. L. Menon
Julia M. L. Menon
GVGunn E. Vist
Gunn E. Vist
SHSebastian Hoffmann
Sebastian Hoffmann

30 October 2026 in Evidence-Based Toxicology
Verified
Journal Article
Open access
MPMilica D. Pavlovic
Milica D. Pavlovic
MLMalgorzata Lagisz
Malgorzata Lagisz
NVNatália B. Videira
Natália B. Videira
JMJulia M. L. Menon
Julia M. L. Menon
GVGunn E. Vist
Gunn E. Vist
SHSebastian Hoffmann
Sebastian Hoffmann

1 January 2025 in Journal of Applied Biotechnology and Bioengineering
Verified
Journal Article
Open access
PDF file
BLBruna Pereira Lopes
Bruna Pereira Lopes
NVNatalia Bernardi Videira
Natalia Bernardi Videira